Geode Capital Management LLC Has $847,000 Stock Holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX)

Geode Capital Management LLC lifted its position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) by 18.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 329,291 shares of the company’s stock after purchasing an additional 50,194 shares during the quarter. Geode Capital Management LLC owned 1.29% of Leap Therapeutics worth $847,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in LPTX. Simplify Asset Management Inc. boosted its holdings in shares of Leap Therapeutics by 67.9% in the second quarter. Simplify Asset Management Inc. now owns 631,269 shares of the company’s stock valued at $1,237,000 after buying an additional 255,293 shares during the period. Marshall Wace LLP boosted its position in shares of Leap Therapeutics by 268.2% during the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock worth $156,000 after buying an additional 58,094 shares during the period. Key Client Fiduciary Advisors LLC grew its holdings in shares of Leap Therapeutics by 13.0% during the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock worth $827,000 after buying an additional 37,067 shares in the last quarter. Valence8 US LP bought a new stake in Leap Therapeutics in the 3rd quarter valued at approximately $48,000. Finally, HighTower Advisors LLC acquired a new position in Leap Therapeutics during the 3rd quarter worth approximately $65,000. Institutional investors own 30.46% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.50 price objective on shares of Leap Therapeutics in a report on Friday, November 15th.

Leap Therapeutics Stock Performance

Shares of NASDAQ LPTX opened at $3.06 on Friday. The stock has a market capitalization of $117.25 million, a PE ratio of -1.59 and a beta of 0.17. Leap Therapeutics, Inc. has a 52 week low of $1.68 and a 52 week high of $4.79. The stock has a 50 day moving average price of $3.05 and a 200 day moving average price of $2.71.

Leap Therapeutics Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.